一名接受格卡瑞韦-哌仑他韦治疗4周失败患者的新型丙型肝炎病毒1型亚型的特征分析。
Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment.
作者信息
Pedersen Martin S, Fahnøe Ulrik, Madsen Lone W, Christensen Peer B, Øvrehus Anne, Bukh Jens
机构信息
Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
出版信息
Microbiol Resour Announc. 2021 Oct 14;10(41):e0075521. doi: 10.1128/MRA.00755-21.
Abstract
Limited information is available in relation to surveillance, genotyping, genome sequences, and treatment outcomes for rare hepatitis C virus variants. Here, we have characterized a novel subtype of major hepatitis C virus genotype 1, which was deep sequenced before and after treatment failure with 4 weeks of glecaprevir and pibrentasvir.
摘要
关于丙型肝炎病毒罕见变异体的监测、基因分型、基因组序列和治疗结果的信息有限。在此，我们对主要丙型肝炎病毒基因1型的一种新型亚型进行了特征分析，该亚型在使用glecaprevir和pibrentasvir治疗4周后治疗失败前后进行了深度测序。
相似文献
1
Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment.
Microbiol Resour Announc. 2021 Oct 14;10(41):e0075521. doi: 10.1128/MRA.00755-21.
2
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426. doi: 10.1016/j.cgh.2017.09.027. Epub 2017 Sep 22.
3
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):839-849. doi: 10.1016/S2468-1253(20)30086-8. Epub 2020 Jul 16.
4
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
Ann Hepatol. 2021 Jan-Feb;20:100257. doi: 10.1016/j.aohep.2020.09.002. Epub 2020 Sep 17.
5
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med. 2018 Jan 25;378(4):354-369. doi: 10.1056/NEJMoa1702417.
6
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Clin Gastroenterol Hepatol. 2020 Oct;18(11):2544-2553.e6. doi: 10.1016/j.cgh.2020.06.044. Epub 2020 Jul 1.
7
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15.
9
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.
Lancet Gastroenterol Hepatol. 2019 Jan;4(1):45-51. doi: 10.1016/S2468-1253(18)30341-8. Epub 2018 Nov 2.
10
Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.01990-17. Print 2018 Mar.
引用本文的文献
1
Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients.
Microbiol Spectr. 2024 Sep 3;12(9):e0064124. doi: 10.1128/spectrum.00641-24. Epub 2024 Jul 25.
2
Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C.
Front Cell Infect Microbiol. 2022 Jun 27;12:885824. doi: 10.3389/fcimb.2022.885824. eCollection 2022.
3
Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.
Viruses. 2022 Mar 16;14(3):614. doi: 10.3390/v14030614.
本文引用的文献
1
Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
Liver Int. 2021 Nov;41(11):2601-2610. doi: 10.1111/liv.14991. Epub 2021 Jul 6.
2
EASL recommendations on treatment of hepatitis C: Final update of the series.
J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018. Epub 2020 Sep 15.
3
IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era.
Mol Biol Evol. 2020 May 1;37(5):1530-1534. doi: 10.1093/molbev/msaa015.
4
Genome Sequence of an Unknown Subtype of Hepatitis C Virus Genotype 6: Another Piece for the Taxonomic Puzzle.
Microbiol Resour Announc. 2019 Oct 17;8(42):e01030-19. doi: 10.1128/MRA.01030-19.
5
Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.
J Hepatol. 2019 Dec;71(6):1099-1105. doi: 10.1016/j.jhep.2019.07.025. Epub 2019 Aug 7.
6
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype.
Nat Biotechnol. 2019 Aug;37(8):907-915. doi: 10.1038/s41587-019-0201-4. Epub 2019 Aug 2.
7
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
Hepatology. 2019 Sep;70(3):771-787. doi: 10.1002/hep.30647. Epub 2019 Jun 5.
8
Full-Length Open Reading Frame Amplification of Hepatitis C Virus.
Methods Mol Biol. 2019;1911:85-91. doi: 10.1007/978-1-4939-8976-8_5.
9
GLUE: a flexible software system for virus sequence data.
BMC Bioinformatics. 2018 Dec 18;19(1):532. doi: 10.1186/s12859-018-2459-9.
10
Hepatitis C and the absence of genomic data in low-income countries: a barrier on the road to elimination?
Lancet Gastroenterol Hepatol. 2017 Oct;2(10):700-701. doi: 10.1016/S2468-1253(17)30257-1.
Zotero 插件